Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Cureline Inc. 1849 Bayshore Highway, Suite 280 BURLINGAME CA 940101214 USA

UEI: SLED_6EDEB17F0707B0BC

Cureline Inc. 1849 Bayshore Highway, Suite 280 BURLINGAME CA 940101214 USA is a federal contractor, registered under UEI SLED_6EDEB17F0707B0BC. It has been awarded $609,161 across 1 federal contract. Primary work spans In-Vitro Diagnostic Substance Manufacturing.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_6EDEB17F0707B0BC

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

$609.2K100%

Awards by NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing$609.2K100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in Cureline Inc. 1849 Bayshore Highway, Suite 280 BURLINGAME CA 940101214 USA's top NAICS codes and agencies

CONTROL, RESPIRATORY PA

Solicitation # SPE2DS-26-T-311F

The BioFire RP2.1/RP2.1plus Control Panel is a synthetic nucleic acid-based quality control product consisting of 12 vials, each containing 300 microliters of a non-infectious buffer solution with stabilizers and preservatives. It is designed for in vitro use with the FilmArray instrument to monitor the detection and identification of respiratory pathogens during RP2.1 panel testing. Each kit provides sufficient reagent for six quality control runs, including six positive and six negative controls. The product requires strict frozenstorage between -25°C and -15°C (-13°F to 5°F) and has a non-extendable shelf life of 18 months, with no more than two months allowed to have passed from the date of manufacture to delivery to the government. Labeling must include the date of manufacture, expiration date, contract number, and lot number in compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must meet commercial standards, ensuring protection against damage, with exterior containers suitable for safe transport at the lowest cost to the specified delivery point. The item is governed by DLA technical and packaging requirements, including RS013 for shelf life, RP001 for packaging standards, and RD003 for potential covered defense information. The National Stock Number is 6550-01-690-4435, with a procurement quantity of three kits under solicitation SPE2DS-26-T-311F, with a delivery deadline of 83 days after award.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 7 hours ago

DEADLINE

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-26-T-308W

The contract is for the procurement of 150,000 units of the QuickVue At-Home OTC COVID-19 Test kit, a rapid antigen detection system designed for self-administration using an anterior nasal swab. Each kit contains all necessary components for two tests, including a tube holder, two prefilled extraction tubes, two swabs, and two test strips with a dipstick format that delivers results in ten minutes through a two-color readout: a blue control line and a red test line. The test is intended for single-user administration, with the two tests in each kit to be performed 24 to 36 hours apart, eliminating the need for additional equipment or laboratory support. Built-in procedural controls ensure test validity, and all materials are pre-assembled for immediate use. The kits are to be delivered within 20 days of award under solicitation SPE2DS-26-T-308W, issued by the Department of Defense’s Medical Supply Chain MD Surg FSF, with performance specified to occur in West Los Angeles, CA. The contract includes adherence to DLA technical and quality requirements under RA001, packaging standards per RP001, and removal protocols for government identification on non-accepted items per RQ011, with the NSN 6550-01-697-6662 identifying the product for federal acquisition purposes.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL SET, GLUCOSE

Solicitation # SPE2DS-26-T-308J

The control set for glucose is designed for use with the Accu-Chek Inform II system and includes two 2.5 mL vials—one each of Level 1 and Level 2 control solutions—to ensure accurate calibration and performance verification of test strips. It must be stored between 39 and 86 degrees Fahrenheit (4 to 30 degrees Celsius) and must not be frozen. The item is issued as a single unit and is subject to strict medical procurement standards, including commercial packaging requirements that ensure protection from damage and safe delivery by common carriers. All units must be marked in accordance with Medical Marking Standard No. 1, which supersedes MIL-STD-129, and include the date of manufacture, expiration or retest date, contract number, and lot number. The item has a non-extendable shelf life of 24 months, and no more than three months may have elapsed from the date of manufacture to the date of government delivery. Technical and quality requirements referenced under R and I numbers are governed by the DLA Master List, with revision standards tied to solicitation or award dates depending on acquisition size. This item is classified as a Type I (Code M) medical supply, and all labeling, packaging, and marking must comply with the latest version of MMS1C. The NSN is 6550-01-642-5011, the solicitation number is SPE2DS-26-T-308J, and delivery is required within 20 days after order award to Fort Campbell, with the contract managed by the Department of Defense under the Medical Supply Chain.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing

Solicitation # 26-008155

The National Institutes of Health Clinical Center plans to award a sole-source firm-fixed-price purchase order to Fisher Scientific for validated reagents and consumable materials essential to the manufacturing of FDA-regulated cell-based therapies used in NIH clinical trials. These materials have been rigorously validated and approved by the Center for Cellular Engineering’s Quality Assurance Department to ensure consistent quality, safety, and efficacy in producing cell therapies for patient care. Any substitution of these materials would necessitate extensive and costly revalidation of manufacturing processes, leading to significant delays and potential risks to ongoing clinical trials, making Fisher Scientific the only viable supplier capable of providing the required validated products and supporting documentation compliant with federal regulatory standards. The acquisition is authorized under FAR 13.106-1(b)(1)(i), which allows for single-source procurement when only one provider can meet the government’s specific requirements, and the value does not exceed the simplified acquisition threshold. The product service code is 6550, and the NAICS code is 325413, classifying the items as in-vitro diagnostic substances. Performance will occur at the NIH Clinical Center in Bethesda, Maryland. While this notice does not solicit bids or proposals, responsible parties may submit capability statements by August 13, 2026, at 6:00 p.m. Eastern Time, referencing POTS 26-008155, though the government retains full discretion to proceed without competition. All inquiries should be directed to Shasheshe Goolsby of the Hospital and Laboratory Support Division.

National Institutes Of Health Olao

POSTED

DEADLINE

CryoStor® CS10, 100 mL Bags for Cell Therapy Manufacturing

Solicitation # 26-007655

The National Institutes of Health Clinical Center plans to award a sole-source firm-fixed-price purchase order to BioLife Solutions for 80 bags of CryoStor® CS10, 100 mL, used exclusively for cryopreserving cell therapy products in FDA-regulated clinical trials. The product is essential to the Center for Cellular Engineering’s manufacturing processes, having been rigorously validated and approved by quality assurance to ensure the safety and consistency of therapies administered to patients. Substituting an alternative cryoprotectant would necessitate extensive revalidation, leading to significant delays, increased costs, and potential disruption to patient care. CryoStor® CS10 is the only commercial cryoprotectant with an FDA Master File and is the only product fully qualified for use in the NIH’s regulated environment, justifying the sole-source designation under FAR 13.106-1(b)(1)(i). The acquisition supports critical clinical research operations at the NIH Clinical Center in Bethesda, Maryland, under PSC 6550 and NAICS 325413. While the notice does not request formal proposals, responsible parties may submit capability statements by August 13, 2026, though the government reserves the right to proceed without competition. All submissions must reference solicitation number 26-007655 and be sent electronically to Shasheshe Goolsby at the NIH Office of Acquisitions and Logistics Management.

National Institutes Of Health Olao

POSTED

DEADLINE

CHIP, HYDROGEN PEROX

Solicitation # SPE2DS-26-T-300S

The contract under solicitation SPE2DS-26-T-300S is for the procurement of one unit of CHIP, HYDROGEN PEROXIDE for use with a CMS analyzer, featuring ten measurement capillaries filled with a substance-specific reagent detection system calibrated to a measuring range of 0.20–2.0 ppm and capable of conducting ten tests. The procurement is managed by the Defense Logistics Agency under the Department of Defense, with a response deadline of August 10, 2026, and a posted date of August 3, 2026. Delivery is required at Camp Carroll, Waegwan, Korea, under FOB Destination terms, with the item to be delivered within 84 calendar days of the request issue date, resulting in an anticipated delivery window ending around October 27, 2026. The contract specifies a fixed-price structure with no option quantities indicated, and while individual unit pricing is listed at $122.00, the total contract value cannot be determined due to incomplete pricing details. Compliance with stringent packaging and marking standards is mandatory, governed by MIL-STD-2073-1E and the Medical Marking Standard No. 1, which supersedes MIL-STD-129 for medical items. Labels must include the date of manufacture, expiration or retest date, contract number, and lot number, with hazardous material labeling adhering to the Hazard Communication Standard and specific submission requirements for hazard warning labels and material safety data sheets prior to award. The contractor must use Wide Area WorkFlow for electronic invoicing and receiving reports, and the government conducts all inspection and acceptance at the delivery point. Numerous FAR and DFARS clauses are incorporated, including those on employment eligibility verification, combating human trafficking, sustainable products, safeguarding contractor information systems, and NIST SP 800-171 compliance, some with deviations allowing for modified application. Offerors must hold a valid Unique Entity ID and CAGE code, submit socioeconomic status representations, and disclose any covered defense telecommunications equipment or joint venture partnerships. All proposals must be submitted electronically via DIBBS, and no physical attachments or formal evaluation factors are specified beyond implicit Low Price Technically Acceptable considerations typical of simplified acquisitions.

Defense Logistics Agency

POSTED

DEADLINE

KIT, PERFORMANCE QUALIF

Solicitation # SPE2DS-26-T-296S

The contract is for the procurement of a single performance qualification kit for electrochemiluminescence (ECL) testing, specifically designed for use with the MSD PR2 Model 1800 instrument. Each kit includes ten plates and corresponding reagents and is classified as a Type I, Code H item with a strict 12-month non-extendable shelf life. The item is regulated by the FDA and must be supplied with full manufacturer and part number disclosure for verification by the contracting officer. Packaging and labeling must strictly follow Medical Marking Standard No. 1, which replaces all references to MIL-STD-129 for medical acquisitions, and all units must be sealed in commercial-grade containers that prevent damage and breakage during transport. Packaging must comply with MIL-STD-2073-1E, and palletization must adhere to DLA Packaging Requirements for Procurement (RP001). The delivery is FOB destination, with the primary delivery location at APO AP 96278-2060 and an alternative freight address at Osan Air Base, South Korea. The item must be delivered within 20 days of solicitation issuance, with an original required delivery date of August 4, 2026, and no quantity variance is permitted. Payment must be processed through Wide Area WorkFlow, and electronic submission of receiving reports is mandatory. The contract incorporates multiple FAR and DFARS clauses related to cybersecurity, safeguarding covered defense information, prohibition of certain foreign telecommunications equipment, hazardous material handling, subcontracting, inspection at destination, and compliance with whistleblower and compensation reporting requirements. Offerors must possess and provide a Unique Entity Identifier (UEI) and CAGE code and are required to represent their size status and socioeconomic certifications, though no such disclosures are completed in the solicitation. All technical and quality requirements referenced are drawn from the DLA Master List of Technical and Quality Requirements, and the contract remains subject to all applicable defense regulations and compliance standards.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

TEST KIT, CORONAVIRUS D

Solicitation # SPE2DS-26-T-296T

The contract specifies the procurement of Abbott BinaxNOW COVID-19 Antigen Self Tests for over-the-counter, at-home use, with a total quantity of five cases, each containing twelve kits and two tests per kit. Each kit must be stored between 2 and 30 degrees Celsius and must have a shelf life of exactly twelve months from the date of manufacture, with no extension permitted. No more than one month may have passed between the date of manufacture and the date of delivery to the government. All packaging must conform to commercial standards and the Medical Marking Standard No. 1, replacing all prior references to MIL-STD-129. Labels on every unit must clearly display the date of manufacture, expiration or retest date, and the contract or lot number. The items must be packed in sealed unit containers that protect against damage and shipped in suitable exterior containers to ensure safe, cost-effective delivery to the designated FPO address. Technical and quality requirements referenced in the DLA Master Listapply, and the procurement is subject to defense information handling protocols. The contract was issued under solicitation SPE2DS-26-T-296T with a response deadline of August 10, 2026, and requires delivery within twenty days of award.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, GLUCOSE

Solicitation # SPE2DS-26-T-295F

The contract specifies the procurement of 8 units of Prodigy Blood Glucose Control Solution High Level 2, a medical solution designed to ensure accurate blood glucose testing with Prodigy monitoring systems. Each unit contains 4 milliliters of solution and must meet strict technical and quality standards outlined in the DLA Master List of Technical and Quality Requirements, including compliance with packaging, labeling, and marking regulations per Medical Marking Standard No. 1, which supersedes MIL-STD-129. The product must be packaged in sealed unit containers and shipped in commercial exterior containers suitable for safe delivery via common carrier at the lowest rate to Fort Hood, Texas, with all labeling including the date of manufacture, expiration date, contract number, and lot number in accordance with MMS1C. The item is classified as a TYPE I (CODE M) with a non-extendable shelf life of 24 months; no more than four months may have elapsed from the date of manufacture to the date of government delivery. Storage requirements mandate temperatures between 36° and 86° Fahrenheit (2° to 30° Celsius) with no freezing. The solicitation, issued under SPE2DS-26-T-295F, requires bidders to clearly specify the source and part number of the supplied goods, with a response deadline of August 10, 2026, and delivery expected within 20 days after award. The procurement is managed by the Department of Defense’s Medical Supply Chain, with Mary-Kathryn Donahue as the primary point of contact.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

CONTROL, BLOOD CHEMI

Solicitation # SPE2DS-26-T-297Y

This contract specifies the procurement of CONTROL, BLOOD CHEMISTRY reagent Level 2, intended for use with the i-STAT PT PLUS cartridge on the i-STAT 1 blood gas analyzer, primarily for coagulation testing. The product is supplied in a box of ten 1.0 mL units and must comply with strict technical and packaging standards, including adherence to Medical Marking Standard No. 1, which replaces MIL-STD-129. The item requires refrigerated storage between 2°C and 8°C (36°F to 46°F) and must not be frozen. The reagent has a non-extendable shelf life of 12 months, with no more than one month allowed to have elapsed from the date of manufacture to the date of government delivery. All packaging must include clear labeling of the date of manufacture, expiration or retest date, contract number, and lot number, in accordance with the latest revision of MMS1C. Packaging must meet commercial standards to ensure safe transport by common carrier at the lowest cost, and all items must be properly sealed and protected from damage. The solicitation number is SPE2DS-26-T-297Y, with a response deadline of August 10, 2026, and delivery must occur within five days of award. The NSN is 6550-01-725-6872, and bidders must clearly identify the source and part number of the supplied item.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC

Solicitation # 36C26026Q0905

The Seattle VA Medical Center is seeking information on the procurement of rapid syndromic molecular testing reagents through a sources sought notice issued under solicitation number 36C26026Q0905. The requirement is aimed at acquiring reagents used for fast and accurate diagnostic testing of infectious syndromes to support clinical care at the facility, with performance located in Seattle, Washington. The request is hosted by the 260-NETWORK Contract Office 20 under the Department of Veterans Affairs, and responses are due by August 6, 2027. No set-aside provisions are being applied, and the NAICS code 325413 indicates this relates to pharmaceutical and medicine manufacturing. The primary point of contact for inquiries is Hector D. Baltazar, with James Harris listed as a secondary contact. All details regarding technical specifications, volumes, and performance requirements are contained in the accompanying attachments, with interested parties encouraged to review them before submitting responses.

260-NETWORK Contract Office 20 (36C260)

POSTED

DEADLINE

in about 1 year

IHS1521817- BPA Freestyle Libre Sensors

Solicitation # IHS1521817_BPA_Freestyle_Libre_Sensors

The Indian Health Service, Chinle Service Unit is seeking information from qualified vendors to establish a blanket purchase agreement for the procurement of Freestyle Libre 3 Plus Sensors and Freestyle Libre 2 Reader Kits, with a tentative delivery date of September 1, 2026. This is a sources-sought notice, not a solicitation, and is intended for market research to inform future contracting decisions, including potential set-asides under the Buy Indian Act and the Small Business Act. Priority will be given to Indian-owned small business economic enterprises, but all eligible firms are encouraged to respond. Only vendors who are authorized distributors of Abbott Diabetes Care may qualify to participate. The requirement falls under NAICS code 325413 with a small business size standard, and all respondents must be registered in SAM.gov at the time of submission and any potential award. Submissions must be sent by August 4, 2026, to the designated point of contact and include a comprehensive company profile with UEI, business size, ownership structure, socio-economic certifications, SAM registrations, and proof of Native American ownership if applicable. Respondents must also provide a statement of capabilities, including relevant past performance, existing contracts such as GSA or VA schedules, and Indian-owned entities must submit the completed IHS IEE Representation Form. No telephone inquiries will be accepted, and no feedback or evaluations will be provided to submitters. Participation is voluntary, and the government assumes no responsibility for costs incurred in responding. The requirement is for supply purchases to support federal health services in Arizona, with performance expected in Chinle, AZ.

Navajo Area Indian Health Svc

POSTED

DEADLINE

GLA VA - 10X Genomics Visium HD kit - Genomics Reagents

Solicitation # 36C26226Q1264

The Department of Veterans Affairs is seeking a qualified small business vendor to supply a 10X Genomics Visium HD kit for spatial single-cell RNA sequencing in support of Dr. Philip Scumpia’s research. The solicitation, identified as 36C26226Q1264, is a small business set-aside under NAICS code 325413 for genomics reagents, with a response deadline of August 18, 2026. The required products include the Visium HD Mouse Transcriptome kit with 8 reactions and the Visium CytAssist Alignment Aid Kit, both of which must be U.S.-made or from designated country end products under federal trade agreements. Proposals must include a formal quote, a letter of authorization from the manufacturer, and full vendor details including business size, socioeconomic classification, UEI number, and confirmation of authorized distributor status if applicable. The contract is being managed by the VA office in Long Beach, California, with performance to occur in Los Angeles, and all inquiries should be directed to Sabrina Schofield.

262F Nco 22 Nonary VA Care (00262F)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Roche Flu Surveillance Testing ReagentThe contract anticipates the procurement of testing reagents for influenza surveillance under the Forensic Sciences Division of the District of Columbia for fiscal year 2026. The initiative is part of a broader public health effort to monitor flu activity, with reagents intended for use in diagnostic and surveillance testing. While specific quantities, delivery timelines, or technical specifications are not detailed in the forecast, the reagents will support laboratory-based detection and analysis of influenza strains across the jurisdiction. This procurement is categorized as a forecast, indicating it is a planning tool for vendors to prepare for an upcoming solicitation, and no formal solicitation number has been issued as of the posting date. The agency responsible, DFS, is based in Washington D.C., and performance is expected to occur within the district, though no specific location is provided. Vendors interested in participating should monitor future official solicitations, as this forecast serves only as an early indicator of intent and does not constitute a binding request for proposals.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Cepheid Norovirus, Mpox, Multiplex ReagentThe contract pertains to the acquisition of testing supplies specifically for the Cepheid Norovirus, Mpox, and Multiplex reagents under the Fiscal Year 2026 forecast for the Department of Forensic Sciences in the District of Columbia. It is categorized as a forecast listing, indicating it is a planned procurement rather than an active solicitation, with no formal solicitation number assigned at this time. The primary focus is on reagents used in diagnostic testing to support forensic and public health laboratories, likely to enhance detection capabilities for infectious agents relevant to criminal investigations and community health monitoring. There is no designated set-aside type, NAICS code, or organizational type specified, and the agency details are limited to the Forensic Sciences division within the District of Columbia, with no明确 office address or place of performance provided. No point of contact information is listed, and the contract remains in a pre-solicitation phase, intended to inform potential vendors of upcoming procurement needs. The associated UI link provides access to the official forecast posting for further details as the procurement process advances.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Qiagen reagentsThe contract forecasts the procurement of Qiagen reagents for forensic science testing applications under the Fiscal Year 2026 budget cycle, managed by the Forensic Sciences division within the District of Columbia. This initiative is tied to laboratory operations requiring reliable molecular diagnostics reagents, likely supporting DNA analysis, sample preparation, or other forensic testing workflows essential to criminal investigations and evidence processing. While the solicitation number and procurement details are not yet available, the posting date indicates this is a future forecast with no set-aside provisions indicated, meaning the opportunity is open to all eligible vendors without geographic or size-based restrictions. The place of performance and organizational details remain unspecified, but the activity is centered within the District of Columbia’s forensic system, suggesting delivery and use will occur at state or local forensic laboratories. No point of contact information is provided at this stage, and the NAICS code, office address, and other typical contracting metadata are also absent, indicating this is an early-stage forecast meant for market research and vendor awareness. Interested suppliers should monitor the official DC contracting portal for future solicitations tied to this forecast, as detailed requirements, timelines, and ordering procedures will be released in subsequent procurement actions.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - IDT Sequencing ReagentThe contract forecast pertains to the procurement of sequencing reagents for the Forensic Sciences Division of the District of Columbia, scheduled for fiscal year 2026. The solicitation is intended to support forensic DNA analysis operations, with the reagents critical to maintaining the accuracy and efficiency of sequencing workflows used in criminal investigations and evidence processing. Despite the lack of specific solicitation numbers, NAICS codes, or set-aside details, the anticipated procurement reflects an ongoing operational need within the agency’s forensic laboratory capabilities. The place of performance and point of contact information are currently unspecified, suggesting the details are still under development or will be finalized closer to the formal solicitation release. The posting date indicates the forecast is publicly available to potential vendors as an early notification ahead of a future bid opportunity, allowing suppliers to prepare proposals and align their offerings with the agency’s requirements.

Forensic Sciences (DFS)

POSTED

DEADLINE

FY26 FR0 DFS/PHL - Illumina AMD reagentsThe District of Columbia’s Forensic Sciences Division is forecasting procurement needs for AMD testing reagents in fiscal year 2026, with the solicitation posted on July 23, 2026. This forecast indicates an upcoming requirement for reagents used in forensic DNA analysis, likely supporting laboratory operations for criminal investigations and evidence processing. The contract is intended for Illumina-branded AMD reagents, suggesting a specific technology platform is preferred for genotyping or sequencing applications in the forensic context. Although the solicitation number, NAICS code, set-aside details, and office location are not yet specified, the procurement is being managed under the agency’s procurement portal and will likely proceed through a formal competitive process. Performance is expected to be delivered within the District of Columbia, aligning with the agency’s operational base. Interested vendors should monitor the official contract portal for the eventual release of a formal request for proposal, as this forecast serves as a preliminary notice to prepare for potential bidding opportunities.

Forensic Sciences (DFS)

POSTED

DEADLINE